NEJM stands by its criticism of Vioxx studyBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7540.505-a (Published 02 March 2006) Cite this as: BMJ 2006;332:505
- Janice Hopkins Tanne
- New York
The New England Journal of Medicine last week reaffirmed the expression of concern that it made last December, about the omission of three heart attacks from a study of rofecoxib (Vioxx) published in 2000. The online editorial was published on 22 February 2006 (http://content.nejm.org, doi: 10.1056/NEJMe068054).
The journal also published responses from 11 authors of the study who are not employed by Merck, the drug's manufacturer, and from two authors who are (doi: 10.1056/NEJMc066096).
The controversy concerns the VIGOR (Vioxx gastrointestinal outcomes research) study, which compared upper gastrointestinal toxicity of rofecoxib with naproxen and was published in the journal in 2000 (New England Journal of Medicine 2000;343: 1520-8).
Last year, the journal editors reviewed electronic documents relating to the study when the journal's executive …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial